Principal Financial Group Inc Chimerix Inc Transaction History

Principal Financial Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	SELL	$1.19 - $2.09 $987 - $1,734	-830 Reduced 2.79%	28,932 $36,000
Q4 2022 Feb 09, 2023	BUY	$1.67 - $2.35 $14,452 - $20,336	8,654 Added 41.0%	29,762 $55,000
Q3 2022 Nov 09, 2022	BUY	$1.81 - $2.76 $1,992 - $3,038	1,101 Added 5.5%	21,108 $40,000
Q2 2022 Aug 10, 2022	BUY	$1.34 - $5.34 $11,671 - $46,511	8,710 Added 77.1%	20,007 $41,000
Q1 2022 May 09, 2022	SELL	$4.58 - $6.8 $44,911 - $66,680	-9,806 Reduced 46.47%	11,297 $52,000
Q4 2021 Feb 09, 2022	SELL	$5.23 - $7.18 $47,504 - $65,215	-9,083 Reduced 30.09%	21,103 $135,000
Q3 2021 Nov 09, 2021	SELL	$5.94 - $8.75 $2,061 - $3,036	-347 Reduced 1.14%	30,186 $186,000
Q2 2021 Aug 10, 2021	BUY	$7.54 - $9.79 $230,218 - $298,918	30,533 New	30,533 $244,000
Q2 2020 Aug 05, 2020	SELL	$1.33 - $3.63 $20,920 - $57,099	-15,730 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$1.27 - $2.33 $82 - $151	65 Added 0.41%	15,730 $23,000
Q4 2019 Feb 05, 2020	BUY	$1.3 - $2.72 $20,364 - $42,608	15,665 New	15,665 $32,000

37M

52.7K

130K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $77.1M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.